U.S. steps up fight against monkeypox, allocates more vaccines

Monkeypox is a viral infection resulting in painful skin sores and has growing cases in the U.S



The U.S. government is stepping up efforts to stop the spread of monkeypox by sending hundreds of thousands of doses of the vaccine to states in the upcoming months, extending access for individuals who are most at risk, and increasing supplies to regions with a high case count. The strategy to prevent monkeypox in regions with the highest transmission and need calls for rapidly extending access to doses of Bavarian Nordic's Jynneos vaccine, which has previously been restricted. The ACAM2000 vaccine from Emergent BioSolutions, which is available in far bigger quantities but has more adverse effects and cannot be used by everyone, including individuals with impaired immune systems, can also be ordered by state and municipal health authorities.


From a national stockpile, the Biden administration will provide 296,000 doses of Jynneos to states and territories in the upcoming weeks, with 56,000 being given out right away and 1.6 million over the course of the following months, according to authorities. Monkeypox, a contagious viral infection similar to smallpox that results in painful skin sores, has more than 350 cases in the United States. Although the virus is prevalent in some regions of Africa, the current outbreak has affected nations where it does not typically travel, raising fears that it may spread even further. "As additional supply becomes available, we will further expand our efforts, making vaccines available to a wider population," Centers for Disease Control and Prevention Director Dr. Rochelle Walensky told reporters.